Enregistrement - Lobbyistes salariés d'entreprises

Objets

• Commerce intérieur
• Commerce international
• Impôts et finances
• Industrie
• Petites entreprises
• Propriété intellectuelle
• Questions touchant les consommateurs
• Relations internationales
• Santé
• Sciences et technologies

Détails sur l'objet

Politique ou Programme

• Innovation, Science and Economic Development Canada's Science & Technology strategy regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
• Patented Medicine Prices Review Board regarding claims of jurisdiction with respect to generic drug products associated with a patent.
• Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
• Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions
• Provide input into guidance with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders.
• Provide input into policy discussions regarding the potential development of a national pharmacare program governments.
• Providing input into the development and implementation of an approval pathway for Subsequent Entry Biologics by Health Canada.
• To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat counterfeit pharmaceutical both nationally and globally.
• participation in consultations, providing comments on modernization of the Food and Drugs Act and related regulations regarding pharmaceuticals

Proposition législative, Projet de loi ou résolution

• Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic Trade Agreement with respect to pharmaceuticals, counterfeit medicines, border measures, and intellectual property.

Règlement

• The need for amendments to the Patented Medicines (Notice of Compliance) Regulations of the Patent Act and address operational concerns such as bringing finality to proceedings under the Regulations; allowing generic manufacturers to amend a Notice of Allegation; and providing meaningful damages and other disincentives to discourage abuse of the Regulatioins by brand name manufacturers.

Techniques de communication

• Communication écrite
• Communication orale

Institutions gouvernementales

• Agence de la santé publique du Canada (ASPC)
• Bureau du Conseil privé (BCP)
• Cabinet du Premier ministre (CPM)
• Chambre des communes
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Finances Canada (FIN)
• Innovation, Sciences et Développement économique Canada (ISDE)
• Santé Canada (SC)
• Secrétariat du Conseil du Trésor du Canada (SCT)
• Sénat du Canada
• Tribunal canadien du commerce extérieur (TCCE)

Adresse :
85 Advance Road
Etobicoke, ON  M8Z 2S6
Canada

Numéro de téléphone : 416-236-2631
Numéro de fax : 416-236-9022  

Renseignements sur la société mère

Mylan Pharmaceuticals ULC n'est pas une filiale d'une société mère.